Volume 6, Issue 2: The Current State of CFTR Modification- PODCAST

e-Cystic Fibrosis Review is a monthly CE series for nurses, nurse practitioners, and others involved in the care of patients with Cystic Fibrosis. It provides updates on the latest research, best practices, and issues currently under debate, as well as a concise review of relevant journal literature.

(Volume 6, Issue 2)


Target Audience

Nurses and health care professionals involved in the care of patients with Cystic Fibrosis.

Learning Objectives

After participating in this activity, the participant will demonstrate the ability to:  

  • Explain the long-term benefits of ivacaftor therapy in people with G551D CFTR mutations.
  • Describe the effects of ivacaftor therapy in people with non-G551D CFTR mutations.
  • Evaluate the impact of lumacaftor plus ivacaftor in people with two F508del CFTR mutations.
  • Describe the current research into therapeutic options for people with CFTR class I also known as nonsense or mis-sense mutations.


Additional information
Contact email: 
Course summary
Available credit: 
  • 0.50 ANCC
  • 0.50 Attendance
Registration opens: 
Registration closes: 
Noah Lechtzin, MD
Director, Adult Cystic Fibrosis Program
Associate Professor of Medicine
Johns Hopkins University
Baltimore, MD


Dr. Noah Lechtzin has reported that he has served as principal investigator for Vertex Pharmaceuticals Incorporated. In addition, he has served as a consultant for Hill Rom.

Unlabeled/Unapproved Uses

Dr. Lechtzin has disclosed that his discussion today will refer to certain off-label or unapproved uses of lumacaftor, ivacaftor, and ataluren

Available Credit

  • 0.50 ANCC
  • 0.50 Attendance


Please login or register to take this course.

Required Hardware/software

Make sure your Adobe flash is updated by clicking HERE